An investigation was performed for architect syphilis tp lot 26001be01.A review of tickets was performed and determined that the reagent lot performs as expected for this product.A review of tracking and trending did not identify any trends for the complaint issue.The customer provided the sample in question and this sample was tested in the course of investigation; results were: architect syphilis tp: 0.38 s/co (non-reactive), recomline treponema igm: negative and recomline treponema igg: borderline (tp453:+, tp15: +/-).In-house testing of retained reagent kits of lot numbers 23137be/26001be was performed.All controls met specifications and no false non-reactive results were obtained, showing that the lots generates the expected results.A review of the manufacturing documentation did not identify any issues associated with the complaint issue.A review of labeling concluded that the issue is sufficiently addressed.Based on the investigation no systemic issue or deficiency of the architect syphilis tp lot 26001be01 was identified.
|